Small interfering RNA (siRNA) has become a powerful tool for selectively silencing gene expression in cultured mammalian cells. In this study, a 67-bp oligonucleotide encoding human telomerase RNA (hTR) was introduced into pSIREN, a shuttle vector for construction of recombinant adenovirus. Then the U6-RNA promoter and siRNA-encoding insert were cut out from the pSIREN and subcloned into pAdeno-X to construct the plasmid pAd-hTR. After the pAd-hTR was transfected into a mammalian cell line HEK-293, adenovirus carrying the hTR-targeting siRNA (Ad-hTR-siRNA) was obtained. We performed a series of experiments to demonstrate silencing of the telomerase mediated by Ad-hTR-siRNA in HeLa cells. Compared with control virus (Ad-NT-siRNA), Ad-hTR-siRNA significantly reduced both hTR mRNA level (by 70.21%) and telomerase activity (by 58.87%) in HeLa cells. Moreover, it induced apoptosis in HeLa cells. Treatment of subcutaneous tumor xenografted with Ad-hTR-siRNA could slow down tumor growth, at least partially due to the induction of apoptosis (Po0.05) in vivo. Taken together, our results demonstrated efficient and specific knockdown of telomerase in HeLa cell line by the hTR siRNA, and indicated the prospect of applying this siRNA expressing recombinant adenovirus system in cancer gene therapy.
Introduction
Telomerase is a specialized reverse transcriptase responsible for synthesizing telomeric DNA at the ends of chromosomes. Telomerase has been found to be upregulated in 85-90% of tumor cells. 1 Thus, telomerase is an attractive target for anti-tumor therapy. Six subunits comprising the telomerase complex have been identified, including human telomerase RNA (hTR), telomeraseassociated protein 1, human telomerase reverse transcriptase (hTERT), heat shock protein 90, p23 and dyskerin. 2 The template region of hTR encompasses 11 nucleotides (5 0 -CUAACCCUAAC-3 0 ), which is complementary to the human telomere sequence (TTAGGG) n . 3 The hTR serves as a template, and together with hTERT, synthesizes and adds new TTAGGG repeats to the ends of telomeres, thereby elongating it.
The RNA component of telomerase is absolutely required for the function of telomerase complex and is therefore a natural target for anti-telomerase agents. 4 Many methods, such as short interfering RNA (siRNA), 5 hammerhead ribozymes 6 and antisense oligonucleotides 7 have been designed to target hTR, especially the template region of the 11 nucleotides. Of these methods, siRNA has been shown to induce strong and efficient RNAi (RNA interference) in mammalian cells. 8, 9 Thus it has been routinely used in gene silencing by transfection of synthesized 21-23 nucleotide siRNA 10 or plasmidderived siRNA. 11 Nevertheless, transient siRNA expression, low and variable transfection efficiency remained problems for chemically synthesized and vector-derived siRNA. 12 Recently, several retrovirus, lentivirus and adenovirus systems have been developed for efficient delivery of siRNA into mammalian cells. [13] [14] [15] These viral vectors have been designed to produce siRNA driven by either the U6 or the H1-RNA promoter for efficient, uniform delivery and immediate knockdown of target gene(s).
In this study, we constructed an adenovirus vector against hTR template region by a ligation method in vitro. 16 We utilized a commercially available adenovirus system and the well-defined polymerase III U6-RNA promoter to deliver the siRNA-expressing cassette into various cell lines. A series of experiments were then conducted to evaluate whether the newly made virus could silence the telomerase by the hTR-specific siRNA in human cancer cells.
Materials and methods
Plasmids and cell lines BD Knockout Adenoviral RNAi System1 kit (cat. no. 631528, BD Biosciences, Franklin Lakes, NJ, USA) was used in this study, which included RNAi-Ready pSIRENShuttle vector (digested by BamHI/EcoRI), pAdeno-X adenoviral vector (digested by PI-SceI/I-CeuI), the negative-control siRNA annealed oligonucleotides, Adeno-X-specific forward and reverse primers, and so on. HEK-293 (a human embryonic kidney cell line), HeLa (a human cervical carcinoma cell line), HepG2 (a human hepatoma cell line), A549 (a human lung carcinoma cell line) and HL-7702 (normal hepatocytes) cells were purchased from the American Type Culture Collection and cultured in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin at 371C in a 5% CO 2 humidified incubator.
Construction of RNAi adenovirus
The siRNA targeting the human telomerase sequence has been described previously. 5 The synthesized 67-bp oligonucleotides (Sangon, Shanghai, China) and complementary oligonucleotides encoding hTR-specific siRNA were 5 0 -GATCCGTTGTCTAACCCTAACTGAGTTCA AGAGACTCAGTTAGGGTAGACAACTTTTTTTCTG CAGG-3 0 and 5 0 -AATTCCTGCAGAAAAAAGTTGTCT AACCCTAACTGAGTCTCTTGAACTCAGTTAGGGT TAGACAACG-3 0 . The target sequence (underlined) corresponds to bases 136-154 of hTR (GenBank accession number U86046). The 67-bp oligonucleotides contained a PstI restriction site immediately downstream of the terminator TTTTTT, allowing confirmation of the cloned insert after ligation and transformation reactions. The oligonucleotides were annealed and ligated to the BamHI and EcoRI sites of RNAi-Ready pSIREN-Shuttle to produce pSIREN-hTR plasmid. The inserted sequences were confirmed by PstI digestion and sequencing (Invitrogen). The negative-control siRNA annealed oligonucleotides were also introduced into pSIREN-NT as described above for hTR. The U6-RNA promoter and the siRNA coding insert were cut from pSIREN-hTR with PI-SceI and I-CeuI, and ligated with pAdeno-X digested by the same restriction enzymes. The products of ligation were transformed into Escherichia coli (DH5a) to get the pAd-hTR. The pAd-hTR was confirmed by restriction enzyme mapping after digestion with XhoI or by double-digestion with PI-SceI and I-CeuI, polymerase chain reaction (PCR) screening for the presence of pSIREN-derived expression cassettes using BD Adeno-X-specific forward and reverse primers, and sequencing. Finally, recombinant adenoviral DNA was linearized with PacI and purified using the DNA UNIQ 10 purified kit (Sangon, China). HEK-293 cells (provided by Professor Wu Qi, Department of Pathophysiology, Sichuan University) were used to pack this adenovirus. HEK-293 cells were seeded (2 Â 10 6 /well) into a six-well plate, cultured for 18 h and transfected with 5 mg PacI linearized pAd-hTR in the presence of Lipofectamine 2000 (cat. no. 11668-027, Invitrogen, at a ratio of 1:2) in serum-free and non-antibiotic medium. After 6 h of incubation, the culture medium was changed to the complete DMEM medium and the plate was incubated at 371C in humidified air containing 5% CO 2 for 2 weeks with medium replacement every 3-4 days to generate adenovirus carrying the hTR-targeting siRNA (Ad-hTRsiRNA). Virus of Ad-hTR-siRNA was harvested, concentrated, titrated, amplified and purified according to the Adenoviral RNAi System's instructions. Ad-NT-siRNA, which derived from pSIREN-NT as a negative virus control, was constructed and packaged in a similar way.
Infection of target cells
Target cells were seeded (10 6 /well) into six-well plates the day before virus infection. Cells were then incubated with recombinant virus (Ad-hTR-siRNA or Ad-NT-siRNA) at 100 MOI. After incubation for 1-2 h, 2 ml of fresh growth medium was added and cells were further incubated and then tested at different times points.
Measurement of telomerase activity reduction
We used HeLa, HepG2 and A549 cell lines to screen for the most sensitive one to hTR siRNA, and HL-7702 as the normal cell control. Cells cultured with DMEM (blank control) and infected with adenovirus Ad-NTsiRNA (negative virus control) or Ad-hTR-siRNA for 3 days were harvested. Telomerase activity was assayed using the TeloTAGGG Telomerase PCR ELISA (TRAP-ELISA) kit (cat. no. 1854666, Roche, Switzerland) following vendor's instructions. Heat-treatment of the cell extract for 10 min at 651C before the TRAP reaction was used to inactivate telomerase activity for producing negative controls. Positive control included in the kit was used. Telomerase activity was expressed by an absorbance (A 450 nm -A 690 nm ). The maximum value of absorbance for the negative control should be 0.25, but for the positive control, it should be higher than 1.5. Samples were regarded as telomerase positive if the difference in absorbance (DA) was 0.2 higher than negative control.
Real-time quantitative PCR for hTR mRNA expression Total RNA was isolated from HeLa cells treated with AdhTR-siRNA or Ad-NT-siRNA for 1, 3 and 6 days using TRIZOL Reagent (cat. no. 15596-026, Invitrogen) and then reverse transcribed using the RevertAid H Minus First Strand cDNA Synthesis Kit (cat. no. #K1621, Fermentas, Lithuania) according to the manufacturer's instructions. The primers for amplifying hTR (a 179-bp fragment) were 5 0 -CTGGGAGGGGTGGTGGCCATT T-3 0 (forward) and 5 0 -CGAACGGGCCAGCAGCTGA CAT-3 05 (reverse). Reaction parameters were 941C for 20 s, 531C for 30 s and 721C for 40 s for 40 cycles. The housekeeping gene, human glyceraldehyde phosphate dehydrogenase (GAPDH), was used as an endogenous reference. The GAPDH primers were 5 0 -CCTCAAGAT CATCAGCAAT-3 0 and 5 0 -CCATCCACAGTCTTCTG GGT-3 0 , which amplified 142-bp fragment. Quantitative PCR was performed using QUANT SYBR Green PCR reagents (cat. no. FP201, TIANGEN, China) based on the manufacturer's protocol. The relative amounts of hTR was normalized to GAPDH using the DD C t method. 17, 18 Alternatively, PCR products of hTR and GAPDH in virus-infected cells were separated on a 2% agarose gel and stained with ethidium bromide.
Flow cytometry for apoptosis Cells were collected and analyzed using fluorescentactivated cell-sorting analysis to determine percentage of cells in the sub-G 1 peak as the primary index of apoptosis. Briefly, HeLa cells were treated with the adenovirus and harvested after 1, 3 and 6 days. Nonadherent cells were collected and combined with adherent cells obtained by trypsinization. The mixture was subsequently pelleted and re-suspended in pre-cooled 70% ethanol to a final concentration of 1 Â 10 6 cells/ml. The cells were fixed overnight at 41C, and then stained with propidium iodide (PI). Finally, DNA content was analyzed using an elite EST flow cytometry (Beckman Coulter, Fullerton, CA, USA). In order to determine the amount of apoptotic cells, a gate was set on living cells in the sub-G 1 phase only.
Anti-tumor assay in vivo
This assay was performed using 4-week-old female BALB/c nu/nu mice (Laboratory animal center of Sichuan University). HeLa cells were suspended as single cell suspension in serum-free DMEM shortly before subcutaneous inoculation into the right armpit. Each mouse received a 0.2 ml of 0.8 Â 10 6 HeLa cells. Tumor volume (expressed in mm
52, where L and l represent the larger and the smaller tumor diameters measured, 19 respectively. Twenty-seven days after implantation, when most of the tumors had reached 7-10 mm in diameter, 19 ,20 the mice were randomized into four groups. Each group had five mice. The mice were intratumorally injected with 0.1 ml of serum-free DMEM alone, or Ad-hTR-siRNA (10 9 PFU/mouse), or Ad-NTsiRNA (10 9 PFU/mouse), or 120 mg of cisplatin (lot. no. 0507024, Qilu Pharmaceutical Co. Ltd, Jinan, China) as positive control. 21 These different treatments were given once every 3 days for 15 consecutive days. After the last injection, mice were observed for 7 days continuously and sacrificed at the end. Tumors were excised, weighed, sectioned and assessed for apoptosis by the terminal deoxynucleotidyl transferase-mediated-dUTP nick-end labeling (TUNEL) assay according to the instructions for a commercial kit (In Situ Cell Death Detection Kit, AP; Roche). Briefly, paraffin-embedded sections were deparaffinized by washing twice with xylene for 5 min, then washing sequentially in 100, 95 and 75% ethanol before being incubated with 10 mg/ml proteinase K for 30 min to strip off nuclear proteins, later incubated in terminal deoxynucleotidyl transferase together with FITC-dUTP at 371C for 60 min. The tissues were immunostained with the addition of the secondary anti-FITC-AP conjugate and AP red (with red color). The counterstaining was performed with hematoxylin (with blue color) for visualization of all cellular nuclei. Histological sections were evaluated using light microscopy ( Â 400). The number of TUNEL-positive cells was counted in five randomly selected fields for each section. The apoptotic index (AI) was given as the percentage of apoptotic nuclei (red) to total nuclei (blue). Appropriate positive and negative controls were used for this experiment.
Statistical analyses
Results were presented mean7s.d. (n ¼ 3). The results of TRAP-ELISA, real-time PCR, tumor volumes and weights were analyzed by analysis of variance. Apoptotic analysis was performed using the Poisson distribution test. Differences were considered statistically significant at Po0.05.
Results

Construction of siRNA-expressing adenoviruses
First, we inserted the 67-bp siRNA oligonucleotide targeting hTR into the siRNA expression vector pSIREN to generate pSIREN-hTR, in which hTR was put under the control of U6-RNA promoter. pSIREN-hTR was digested by PstI and one band appeared as expected. The sequencing confirmed the authenticity of the 67-bp hTRtargeting sequence in pSIREN-hTR (data not shown). Next, we shuttled the hTR siRNA into the adenoviral vector, pAdeno-X (Figure 1a) , to construct pAd-hTR (Figure 1b) , that presumably drives the transcription of a siRNA hairpin fragment against hTR, a stem-loop RNA with 19-nucleotide stem and 9-nucleotide loop ( Figure 1c) . The results of pAd-hTR identification were just as Figure 2 . Six bands were observed in the XhoI digestion and one band appeared in the PI-SceI/I-CeuI digestion. An expected, 287 bp was amplified by PCR, as indicated by the arrow in Figure 2 . Sequencing results demonstrated that pAd-hTR included a portion of pSIREN, the 67-bp oligonucleotide insert and a portion of pAdeno-X (data not shown). The RNA hairpin expressed by the pAd-hTR was shown in Figure 1c . It would be further processed into bioactive siRNA by the removal of the loop sequence by Dicer, the mammalian homolog of the RNase III nuclease. The titers of viruses packaged in HEK-293 cells (Ad-hTR-siRNA and Ad-NTsiRNA) were 1.3 Â 10 10 and 1.5 Â 10 10 PFU/ml.
Expression of telomerase activity in different cell lines with siRNA treatment in vitro
In our TRAP-ELISA, the A 450 nm -A 690 nm of negative control was 0.10, positive control was 1.60. Telomerase activity of HeLa, HepG2, A549 and HL-7702 cells treated for 3 days with DMEM, Ad-NT-siRNA and Ad-hTRsiRNA was shown in Figure 3 . Overall, telomerase activity had no significant difference between these two control groups and different cells. Analysis of telomerase activity in the Ad-hTR-siRNA groups showed a significant reduction as compared with the controls. Inhibition of hTR mRNA expression in HeLa cells infected with Ad-hTR-siRNA At 1, 3 and 6 days after infection, hTR mRNA expression in Ad-hTR-siRNA-treated HeLa cells decreased gradually compared with that in Ad-NT-siRNA-treated HeLa cells. Especially at 6 days after infection, the relative amount of target hTR mRNA was decreased up to 70.21% (Amount in Ad-NT-siRNA-Amount in Ad-hTRsiRNA)/Amount in Ad-NT-siRNA Â 100% ¼ (0.94À0.28)/ 0.94 Â 100% (Figure 4a) . A representative gel was presented in Figure 4b . The weaker hTR bands were seen at days 3 and 6 after Ad-hTR-siRNA infection, but a similar band of GAPDH was observed in every lane.
Ad-hTR-siRNA infection increased apoptotic rate of HeLa cells
The apoptosis rate was 29.7% in HeLa cells treated with Ad-hTR-siRNA for 6 days, whereas it was only 10.6% in HeLa cells treated with Ad-NT-siRNA. We also observed that at days 1 and 3, the percentages of apoptosis were 3.8, 5.2% (treated with Ad-NT-siRNA) and 3.3, 6.1% 
Anti-tumor activity of Ad-hTR-siRNA in vivo
The results of experiments in vitro demonstrated that the Ad-hTR-siRNA could efficiently inhibit expression of hTR mRNA and telomerase activity, and increase apoptosis in HeLa cells. Therefore, we further investigated the anti-tumor effect of this virus in vivo. Tumors implanted were established in the right armpit of 20 mice with HeLa cells. The control groups treated with DMEM and Ad-NT-siRNA showed a continuous increase in tumor size, while the Ad-hTR-siRNA group showed suppression of tumor growth. The tumors began to expand again after Ad-hTR-siRNA treatment finished ( Figure 5 ), but they were smaller than that of negative controls obviously. In cisplatin group, it was difficult to observe any obvious tumors when the mice were killed on day 22, so cisplatin led to a substantial suppression of tumor growth. The mean tumor volumes and weights were showed in Table 1 . They had significant reduction in the Ad-hTR-siRNA and cisplatin treatment groups as compared to the DMEM and Ad-NT-siRNA group, respectively. There was no difference between the DMEM and Ad-NT-siRNA groups. When the tumor xenografts were removed at day 22, their shapes were irregular and central necrosis was observed in most of the implanted tumors. After TUNEL staining, tumor tissues in DMEM and Ad-NT-siRNA control groups showed characteristics of squamous cell carcinoma, including the arrangement of tumor cells nuclei in cord or nest forms (Figure 6a and b) , whereas in Ad-hTR-siRNA group, a number of TUNELpositive cells were observed (Figure 6c ). These nuclei most often displayed typical alterations such as pyknosis, crescent-like condensation of chromatin or segregation into apoptotic bodies. Fibrous scar had formed in cisplatin group (Figure 6d ). In the control group, few TUNELpositive cells were detected (Figure 6a, b and d) , and the AI was (0.570.2)%, (0.670.2)% and (0.370.2)%, separately; there were no statistically significant differences among them. The AI of Ad-hTR-siRNA group was (15.972.1)%; it had a significant increase. Figure 4 Adenovirus siRNA-mediated suppression of hTR mRNA expression. (a) Relative hTR mRNA levels in transfected HeLa cells. Cells were infected with Ad-hTR-siRNA or Ad-NT-siRNA as described. RNA was isolated at the indicated time points (days 1, 3 and 6), then reverse transcribed to cDNA and subjected to real-time quantitative polymerase chain reaction (PCR). Expression of hTR was normalized to glyceraldehyde phosphate dehydrogenase (GAPDH) (endogenous control). Error bars indicate standard error and represent three independent experiments. (b) PCR amplification products of hTR and GAPDH in two groups were also separated on agarose gels and visualized by EB staining. 
Discussion
In this study, we developed a new adenovirus Ad-hTRsiRNA system against the template region of hTR. The efficiency of this system was improved by an in vitro ligation method, which was easy to manipulate compared to homologous recombination in E. coli. 16 Because of deletions in E1 and E3 genes of adenovirus, Ad-hTRsiRNA was replication deficient 22 ; however, infectious Ad-hTR-siRNA viral particles could be obtained by packaging in HEK-293 cells. The recombinant Ad-hTRsiRNA demonstrated high efficiency in inhibiting telomerase activity on HeLa, HepG2 and A549 tumor cell lines, but without apparent effect on HL-7702 cells. The rapid reduction of hTR mRNA in HeLa cells suggested that the Ad-hTR-siRNA effectively knocked down the expression of telomerase in tumor cells. But the recombinant Ad-NT-siRNA neither inhibited telomerase activity nor reduced hTR mRNA. It suggested that the effect of hTR siRNA in decreasing telomerase RNA was sequence specific, tumor specific and susceptible. The apparent susceptibility could be explained as follows. Telomerase acts in the nucleus and hTR contains a nucleolar localization signal. 23 Ad-hTR-siRNA contains U6 siRNA promoter cassette expressing siRNA in nucleoplasm, 24 so Ad-hTR-siRNA might induce RNAi against hTR directly in the nucleus. Moreover, Ad-hTR-siRNA has many additional advantages in terms of anti-tumor therapy, such as low cost, targeting both proliferative and nonproliferative tumor cells, and easy delivery.
Other studies had shown that targeting hTR via antisense strategies led to induction of apoptosis. However, feasibility of employing an adenovirus-based siRNA delivery approach to target hTR had not been studied so far. Could this system knock down hTR and trigger cell death simultaneously? Our PI-staining showed that Ad-hTR-siRNA could induce tumor cell apoptosis in a time-dependent manner. Interestingly, Ad-hTR-siRNA infection of HeLa cells caused massive apoptosis (29.7%) at as early as 6 days after the treatment. The next question was what was the molecular mechanism of apoptotic induction in tumors treated with Ad-hTR-siRNA within 6 days? To answer this question, the following two observations, which were under another study, might provide insights. (1) Other types of conditional telomerase inhibitors often led to a delayed inhibition of cell growth only after sufficient telomere shortening upon many cycles of cell division. 25 Fast inhibition of telomerase activity and induction of apoptosis had been accomplished by hammerhead ribozymes against the hTERT T motif, anti-sense techniques 26 and CFP-2 (a bioactive polysaccharide from Cranioleuca furcata). 27 The underlying mechanism in which Ad-hTR-siRNA quickly induced tumor cell apoptosis was based on the repression of telomerase activity by interfering hTR that likely caused both shortening of telomere and alteration of telomerase complex, since changes in the structure of the telomere complex could cause uncapping of the telomeric ends, resulting in DNA damage and rapid induction of apoptosis. 28 (2) Ad-hTR-siRNA might directly or indirectly stimulate the apoptotic pathways regardless of telomere length in tumors, such as caspase or p53 pathway. Certainly, the detailed mechanisms regarding how Ad-hTR-siRNA activates this high incidence of apoptosis in such a relatively short time are still far from clear and warrant further future studies. Under the current treatment protocol in nude mice, AdhTR-siRNA appeared to be less efficient than cisplatin. The following reasons might account for the lower efficiency of Ad-hTR-siRNA in vivo. (1) The adenoviral genome of Ad-hTR-siRNA, just like many other adenovirus-based gene delivery systems, 29 remained episomal, resulting in only transient expression of hTR siRNA. Therefore, once treatment was terminated, the tumor began to grow again. (2) Injection of Ad-hTR-siRNA virus particles into tumor did not result in the infection of all tumor cells in the established tumor mass due to presumably the inability of viral particles to diffuse widely enough to reach all tumor cells. (3) In contrast to cisplatin that has multiple effects on actively proliferating tumor cells, 30 Ad-hTR-siRNA maybe acted solely on downregulation of tumor cell telomerase activity. To overcome some of these limitations, the mode and efficiency of delivery has to be improved in the future. In addition, Ad-hTR-siRNA should also be utilized in conjunction with other anti-tumor treatments in order to achieve more efficient anti-tumor effect. However, as compared with DMEM and Ad-NT-siRNA controls, Ad-hTR-siRNA had impressive anti-tumor effect. Among these three groups, tumor volume (555768 mm 3 ) and tumor weight (0.22670.023 g) of the Ad-hTR-siRNA group were the lowest, whereas AI (15.972.1%) was the highest. The capability of Ad-hTR-siRNA to inhibit tumor growth in nude mice was likely due to a combination of inhibition of tumor cell telomerase activity and induction of tumor cell apoptosis and/or necrosis, as was the case in the HeLa cell line. Overall, our study has demonstrated that adenovirus-mediated delivery of siRNA could be an effective approach to silence gene expression of hTR in tumor cells for anti-tumor gene therapy.
